| DB ID | MyCo_1048 |
| Title | Aspergillosis in Critically Ill Patients with and Without COVID-19 in a Tertiary Hospital in Southern Brazil |
| Year | 2024 |
| PMID | 38847987 |
| Fungal Diseases involved | Aspergillosis |
| Associated Medical Condition | Critically Ill Patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Research Ethics Committee in the Health Area of the Federal University of Rio Grande (CEP/FURG), process 234/2018. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | Eighty-seven patients were included in the study. |
| Cohort No. | 87 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | Aspergillus galactomannan lateral flow assay (GM) (IMMY, Norman, OK, USA) |
| ELISA kits | None |
| Assay Data | Aspergillus galactomannan lateral flow assay (GM) (IMMY, Norman, OK, USA) |
| Validation Techniques used | Aspergillus galactomannan lateral flow assay+qPCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
